Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)

NCT04595617 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT04595617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04595617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)
Lead sponsor
University Hospital, Bordeaux
Phase
Not applicable
Overall status
Completed
Start date
January 6, 2021
Completion date
July 6, 2023
Enrollment
28 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glanzmann thrombasthenia